Press Releases

Merck, BMS Rake in Billions as Big Pharma Continues Price-Gouging Campaign

Big Pharma
October 31, 2024

Today, pharmaceutical leaders Merck and Bristol Myers Squibb (BMS) each reported their Q3 2024 earnings, with results reaching $3.2 and $1.2 billion, respectively. Both companies manufacture drugs selected for the Biden-Harris administration’s historic Medicare price negotiation program and are actively pursuing legal action to halt the program’s i

Press Releases

Watchdog: Big Pharma Back in Court Defending “Right” to Price Gouge Seniors

Economic Security and Corporate Power
October 30, 2024

Today, AstraZeneca, Bristol Myers Squibb and Janssen will deliver opening arguments before the Third Circuit Court of Appeals for their case against the Biden-Harris administration’s historic Medicare negotiation program. Since President Biden signed the Inflation Reduction Act into law, the pharmaceutical industry has filed at least 9 lawsuits

Press Releases

Novartis Doubles Profits While Suing to Block Biden-Harris Rx Drug Negotiation Program Lowering Seniors’ Costs

Economic Security and Corporate Power
October 29, 2024

Today, Novartis—one of several pharmaceutical companies still suing the Biden-Harris administration to block Medicare from negotiating lower prescription drug prices—announced $3.2 billion in Q3 2024 earnings, a 111% increase from 2023, thanks to “sales growth driven by continued strong performance from Entresto.”

Press Releases

Analysis: Amid DOT Rulemaking, Airline Industry Spent $26M to Keep Junk Fees Hidden

Junk Fees
October 28, 2024

Today, the Biden-Harris administration revealed its final rule requiring airlines to be more transparent about pricing and to provide automatic cash refunds to customers with delayed or canceled flights. Alongside the announcement, new research from government watchdog Accountable.US revealed today that Airlines for America, a trade group, and six

back to top